Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease

Summary

The purpose of this study is to evaluate the proof of concept of efficacy of ustekinumab in subjects with Behçet disease, including patients with oral ulcers (STELABEC-1) and patients with active posterior uveitis or panuveitis (STELABEC-2)

Timeline

Start

2017-06-14

Primary completion

2019-05-07

Completion

2019-11-19

Publications

• Results Revel MP, Chassagnon G, Sanchez O, Ferretti G, Millet I, Rocher L, Maitre S, Lederlin M, Ducou-le-Pointe H, Rousset P, Bennani S, Zins M, Bruneau B, Tissot V, Alison M, Canniff E, Siauve N, Vandeventer S, Le Blanche AF, Planquette B, Tsatsaris V, Coste J. CT venography for the diagnosis of postpartum venous thromboembolism: a prospective multi-center cohort study. Eur Radiol. 2024 Nov;34(11):7419-7428. doi: 10.1007/s00330-024-10791-8. Epub 2024 May 23.
• Results London J, Regent A, Dion J, Jilet L, Jachiet M, Lidove O, Cohen-Aubart F, Aractingi S, Guegan S, Pennaforte JL, Abdoul H, Puechal X, Terrier B. Efficacy and safety of ustekinumab in Behcet disease: Results from the prospective phase 2 STELABEC trial. J Am Acad Dermatol. 2022 Sep;87(3):681-684. doi: 10.1016/j.jaad.2021.11.045. Epub 2021 Dec 2. No abstract available.

Drugs

Indications